About PHAXIAM
PHAXIAM is a company based in Lyon (France) founded in 2004. PHAXIAM has raised $15.8 million across 8 funding rounds from investors including AXA, Bpifrance and Idinvest Partners. PHAXIAM offers products and services including Phage Therapy and Clinical Portfolio. PHAXIAM operates in a competitive market with competitors including Gubra, Gentronix, Tigermed, Shanghai Semero Biotechnology and BioQual, among others.
- Headquarter Lyon, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Phaxiam Therapeutics
-
Annual Revenue
Not available
-
Net Profit
-$25.92 M (USD)-10524.11as on Dec 31, 2023
-
EBITDA
-$26.28 M (USD)15.84as on Dec 31, 2023
-
Total Equity Funding
$15.8 M (USD)
in 8 rounds
-
Latest Funding Round
$308.3 K (USD), Grant
Jan 01, 2020
-
Investors
AXA
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PHAXIAM
PHAXIAM offers a comprehensive portfolio of products and services, including Phage Therapy and Clinical Portfolio.
Uses bacteriophages to target and eradicate resistant bacteria effectively.
Manages phage-based solutions for severe infections through research.
People of PHAXIAM
Unlock access to complete
Funding Insights of PHAXIAM
PHAXIAM has successfully raised a total of $15.8M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $308.3 thousand completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PHAXIAM
PHAXIAM has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include AXA, Bpifrance and Idinvest Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Equity investments are provided to low and middle market companies.
|
Locked | Locked | Locked | |
|
Karista is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Auriga Partners in France.
|
Locked | Locked | Locked |
Investor details for PHAXIAM
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PHAXIAM
Investment portfolio details for PHAXIAM
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PHAXIAM
Detailed financials for PHAXIAM
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Phaxiam Comparisons
Peer comparison for PHAXIAM
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PHAXIAM
PHAXIAM operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gubra, Gentronix, Tigermed, Shanghai Semero Biotechnology and BioQual, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Preclinical CRO services for NAFLD/NASH, diabetes, and obesity are provided.
|
|
| Locked | Locked | Locked |
In-vitro and in-vivo genetic toxicology screening services are provided.
|
|
| Locked | Locked | Locked |
Drug development and preclinical services are provided by Tigermed.
|
|
| Locked | Locked | Locked |
Diversified preclinical services for brain-related disorders are provided.
|
|
| Locked | Locked | Locked |
Contract research on infectious disease models is conducted.
|
|
| Locked | Locked | Locked |
Preclinical services in immunology, regeneration, neuroscience, and histology are provided.
|
Detailed competitors of PHAXIAM
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Phaxiam
Complete news archive for PHAXIAM
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PHAXIAM
PHAXIAM was founded in 2004 and raised its 1st funding round 2 years after it was founded.
PHAXIAM is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
PHAXIAM is a funded company, having raised a total of $15.8M across 8 funding rounds to date.
PHAXIAM was founded in 2004 and is headquartered in Lyon, France, within the biopharmaceutical sector. Antibacterial therapies based on bacteriophage viruses are developed by the company to address bacterial infections in humans, particularly those resistant to conventional treatments. Operations focus on research and development of these innovative solutions. Recent activities include announcements of collaborations and research partnerships, alongside receipt of a compliance notice from Nasdaq.
PHAXIAM's top competitors include Gubra, BioQual and BTS Research.
PHAXIAM offers Phage Therapy and Clinical Portfolio.
PHAXIAM has 6 investors. Key investors include AXA, Bpifrance, Idinvest Partners, European Union, and Karista.